Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
Medtronic
Express Scripts
AstraZeneca

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Galeterone


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Galeterone?

Galeterone is an investigational drug.

There have been 4 clinical trials for Galeterone. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Tokai Pharmaceuticals, Novus Therapeutics, Inc, and Educational & Scientific LLC.

There are one hundred and eighteen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Galeterone
TitleSponsorPhase
1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic AdenocarcinomaUniversity of Maryland, BaltimorePhase 2
Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled GaleteroneEducational & Scientific LLCPhase 1
Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled GaleteroneTokai PharmaceuticalsPhase 1

See all Galeterone clinical trials

Clinical Trial Summary for Galeterone

Top disease conditions for Galeterone
Top clinical trial sponsors for Galeterone

See all Galeterone clinical trials

US Patents for Galeterone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Galeterone ⤷  Sign up for a Free Trial Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Sign up for a Free Trial
Galeterone ⤷  Sign up for a Free Trial Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) GTX, INC. (Memphis, TN) ⤷  Sign up for a Free Trial
Galeterone ⤷  Sign up for a Free Trial Selective androgen receptor degrader (SARD) ligands and methods of use thereof GTX, INC. (Memphis, TN) ⤷  Sign up for a Free Trial
Galeterone ⤷  Sign up for a Free Trial Humanized anti-ACTH antibodies and use thereof ALDER BIOPHARMACEUTICALS, INC. (Bothell, WA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Galeterone

Drugname Country Document Number Estimated Expiration Related US Patent
Galeterone Argentina AR107432 2036-01-11 ⤷  Sign up for a Free Trial
Galeterone Australia AU2017207268 2036-01-11 ⤷  Sign up for a Free Trial
Galeterone Australia AU2019203280 2036-01-11 ⤷  Sign up for a Free Trial
Galeterone Australia AU2021201018 2036-01-11 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
Medtronic
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.